


CLAIMS

1. A compound of formula (I):



5 wherein:

R^1 is phenyl optionally substituted by halogen, cyano, C_{1-4} alkyl or C_{1-4} haloalkyl;

R^2 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl; and,

R^3 is a group having an NH or OH that has a calculated or measured pKa of 1.0 to 8.0;

10 or a pharmaceutically acceptable salt thereof.

2. A compound of formula (I) as claimed in claim 1 wherein R^1 is phenyl substituted with one, two or three of: halogen, cyano or C_{1-4} alkyl.

- 15 3. A compound of formula (I) as claimed in claim 1 or 2 wherein R^2 is hydrogen.

4. A compound of formula (I) as claimed in claim 1, 2 or 3 wherein the acidic NH of R^3 is part of a ring or part of a substituent on an aryl or heterocyclyl ring.

- 20 5. A compound of formula (I) as claimed in claim 1, 2 or 3 wherein the acidic OH of R^3 is a substituent or part of a substituent on an aryl or heterocyclyl ring.

6. A compound of formula (I) as claimed in claim 1, 2, 3 or 4 wherein the acidic NH of R^3 is part of a suitably substituted 2-oxo-thiazol-5-yl, 2-oxo-oxazol-5-yl, 2-oxo-imidazol-5-yl, 1H-1,2,3-triazol-4-yl, 4-oxo-1H-1,4-dihydropyridin-3-yl, 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl, 6-oxo-1H-1,6-dihydropyridin-3-yl or 2H-tetrazol-5-yl ring.
- 25

7. A compound of formula (I) as claimed in claim 1, 2 or 3 wherein R^3 is:


- 30 • 2-oxo-thiazol-5-yl having a suitable electron withdrawing substituent in the 4-position;

- 2-oxo-oxazol-5-yl having a suitable electron withdrawing substituent in the 4-position;
- 1H-1,2,3-triazol-4-yl having a suitable substituent in the 5-position;
- 4-oxo-1H-1,4-dihydropyridin-3-yl having a suitable electron withdrawing substituent in the 2-position;
- 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl having a suitable substituent in the 3-position and optionally substituted in one or more other ring positions;
- 6-oxo-1H-1,6-dihydropyridin-3-yl having a suitable electron withdrawing substituent in the 2-position and/or the 5-position and optionally substituted in one or more other ring positions;
- 6-oxo-1H-1,6-dihydropyridin-3-yl having $\text{CH}_2\text{CO}_2\text{H}$ on the ring nitrogen and optionally substituted in one or more other ring positions;
- 2H-tetrazol-5-yl;
- a CO_2H , $\text{CH}_2\text{CO}_2\text{H}$ or $\text{OCH}_2\text{CO}_2\text{H}$ group on an optionally substituted phenyl, optionally substituted $\text{CH}_2\text{Ophenyl}$ or optionally substituted naphthyl ring; or,
- an $\text{NHS(O)}_2(\text{C}_{1-4} \text{ alkyl})$ group on an optionally substituted aromatic heterocyclyl ring;


or, where possible, a tautomer thereof.

8. A compound of formula (I) as claimed in claim 1, 2, 3, 4, 6 or 7 wherein R^3 is:
- 2-oxo-thiazol-5-yl having a suitable electron withdrawing substituent in the 4-position;
 - 1H-1,2,3-triazol-4-yl having a suitable substituent in the 5-position; or,
 - 6-oxo-1H-1,6-dihydropyridin-3-yl having C_{1-4} fluoroalkyl or cyano in the 2-position or the 5-position.

9. A compound of formula (I) as claimed in claim 1, 2, 3, 4, 5, 6, 7 or 8 wherein the 2-hydroxy group has the stereochemistry shown below:



10. A process for preparing a compound as claimed in claim 1, the process comprising reacting a compound of formula (II):



wherein R^1 and R^2 are as defined in claim 1, with a compound of formula (III):



wherein L^1 is a leaving group, and R^3 is as defined in claim 1; in the presence of a base, optionally in the presence of a coupling agent;

11. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier therefor.

12. A compound of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, for use in therapy.

13. A compound of formula (I), or a pharmaceutically acceptable salt thereof as claimed in claim 1, in the manufacture of a medicament for use in therapy.

14. A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1.